- GVHD is a major impediment to successful allogeneic bone marrow transplantation for establishing remission from leukemias and non-Hodgkin's lymphomas. This competing renewal is a continuation of research initiated in l995 devoted to understanding mechanisms that underlie the cellular pathology of GVHD. During previous cycles, a relevant murine model for human GVHD has been developed and characterized. An in vivo bioassay for GVHD-like cytotoxicity in human skin also has been described. The investigators have learned that tissue injury in cutaneous acute GVHD has at least three phases: i) Allostimulation whereby donor T cells are activated via antigen binding to CD4 surface molecules associated with the T-cell receptor-CD3 complex; ii) homing of activated donor cells to specific organs as a result of expression of adhesion molecules by cytokine-activated microvascular endothelial cells; and iii) cytotoxicity involving selective apoptosis of specific subpopulations of target cells. Allostimulation, homing, and cytotoxic phases, respectively, involve direct interactions between T cells and antigen presenting cells, T cells and endothelial cells, and T cells and target keratinocytes. Such interactions are potential targets for therapeutic intervention. The investigators have successfully inhibited experimental murine GVHD by use of synthetic peptides designed specifically to mimic the CDR3 region of the D1 immunoglobulin domain of the murine and human CD4 molecule. They hypothesize that the efficacy of this approach lies in blunted induction of T-cell allostimulation and cytotoxic capacity as well as inhibition of T-cell homing to specific target tissues. They now plan to explore mechanisms whereby murine CD4-CDR3 peptide abrogates target cell apoptosis in GVHD. A novel synthetic peptide that mimics the FceRIa molecule on mast cells and that appears also to inhibit this disease will be studied. In addition, they will evaluate peptide administration protocols in experimental GVHD to assess the practical utility of this novel therapeutic approach. Finally, they will evaluate mechanisms of immunomodulatory strategies, including the CD4-CDR3 peptide, to inhibit human cutaneous cytotoxicity in an in vivo chimeric model relevant to human disease. These data should expand present understanding of key early events that result in potentially lethal tissue damage in acute GVHD, and assist in evaluating synthetic peptides as relevant therapeutic strategies for human disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA040358-11
Application #
2615977
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Mccarthy, Susan A
Project Start
1992-12-01
Project End
2002-02-28
Budget Start
1998-05-22
Budget End
1999-02-28
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Pathology
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Ramirez-Montagut, Teresa; Chow, Andrew; Kochman, Adam A et al. (2007) IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. J Immunol 179:1669-80
DiRienzo, Christine G; Murphy, George F; Friedman, Thea M et al. (2007) T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 13:265-76
Zhan, Qian; Signoretti, Sabina; Whitaker-Menezes, Diana et al. (2007) Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol 127:106-15
Durakovic, Nadira; Bezak, Karl B; Skarica, Mario et al. (2006) Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol 177:4414-25
DiRienzo, Christine G; Murphy, George F; Jones, Stephen C et al. (2006) T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease. Biol Blood Marrow Transplant 12:818-27
Clark, Rachael A; Chong, Benjamin F; Mirchandani, Nina et al. (2006) A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol 126:1059-70
Sugerman, Philip B; Faber, Sara B; Willis, Lucy M et al. (2004) Kinetics of gene expression in murine cutaneous graft-versus-host disease. Am J Pathol 164:2189-202
Friedman, Thea M; Jones, Stephen C; Statton, Debbie et al. (2004) Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant 10:224-35
Choksi, Swati; Kim, Judith C; Whitaker-Menezes, Diana et al. (2004) A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Biol Blood Marrow Transplant 10:669-80
Jones, Stephen C; Friedman, Thea M; Murphy, George F et al. (2004) Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol Blood Marrow Transplant 10:91-105

Showing the most recent 10 out of 77 publications